<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To design a <z:chebi fb="7" ids="16670">peptide</z:chebi> disrupting the interaction between N-<z:chebi fb="36" ids="29309">methyl</z:chebi>-d-<z:chebi fb="0" ids="29995">aspartate</z:chebi> receptors-2B (NR2B) and postsynaptic density protein-95 (PSD-95), a gene fragment encoding a chimeric <z:chebi fb="7" ids="16670">peptide</z:chebi> was constructed using polymerase chain reaction and ligated into a novel expression vector for recombinant expression in a T7 <z:chebi fb="40" ids="33697">RNA</z:chebi> polymerase-based expression system </plain></SENT>
<SENT sid="1" pm="."><plain>The chimeric <z:chebi fb="7" ids="16670">peptide</z:chebi> contained a fragment of the cell membrane transduction domain of the human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus type1 (HIV-1) Tat, a <z:e sem="disease" ids="C0021400" disease_type="Disease or Syndrome" abbrv="FLU">influenza</z:e> virus hemagglutinin (HA) <z:chebi fb="0" ids="53000">epitope</z:chebi>-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c) </plain></SENT>
<SENT sid="2" pm="."><plain>We named the chimeric <z:chebi fb="7" ids="16670">peptide</z:chebi> Tat-HA-NR2B9c </plain></SENT>
<SENT sid="3" pm="."><plain>The expression plasmid contained a gene fragment encoding the Tat-HA-NR2B9c was ligated to the C-terminal fragment of l-asparaginase (AnsB-C) via a unique acid labile Asp-Pro linker </plain></SENT>
<SENT sid="4" pm="."><plain>The recombinant fusion protein was expressed in inclusion body in Escherichia coli under <z:chebi fb="0" ids="30353">isopropyl</z:chebi> Î²-d-1-thiogalactopyranoside (IPTG) and purified by washing with 2M <z:chebi fb="20" ids="16199">urea</z:chebi>, solubilizing in 4M <z:chebi fb="20" ids="16199">urea</z:chebi>, and then <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> precipitation </plain></SENT>
<SENT sid="5" pm="."><plain>The target chimeric <z:chebi fb="7" ids="16670">peptide</z:chebi> Tat-HA-NR2B9c was released from the fusion partner following acid hydrolysis and purified by isoelectric point precipitation and ultrafiltration </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="26" ids="8984">SDS</z:chebi>-PAGE analysis and MALDI-TOF-MS analysis showed that the purified Tat-HA-NR2B9c was highly homogeneous </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, we investigated the effects of Tat-HA-NR2B9c on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced cerebral injury in the rats subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) and reperfusion, and found that the <z:chebi fb="7" ids="16670">peptide</z:chebi> reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improved neurological functions </plain></SENT>
</text></document>